# China NMPA Drug Inspection - Guangxi Yulin Huaantang Traditional Chinese Medicine Pieces Co., Ltd. - Rhodiola rosea

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/guangxi-yulin-huaantang-traditional-chinese-medicine-pieces-co-ltd/e5d62261-df13-46aa-a56f-eba4d68c4109/
Source feed: China

> China NMPA drug inspection for Guangxi Yulin Huaantang Traditional Chinese Medicine Pieces Co., Ltd. published August 20, 2020. Drug: Rhodiola rosea. The National Medical Products Administration (NMPA) issued an announcement on August 20, 2020, detailing findings from d

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 55 of 2020 from the National Medical Products Administration regarding 25 batches of drugs that did not meet the requirements.
- Company Name: Guangxi Yulin Huaantang Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2020-08-20
- Drug Name: Rhodiola rosea
- Inspection Finding: [Characteristics]
- Action Taken: Risk control measures such as suspending sales and use, and recalling products; initiating investigations and publicly disclosing the results.
- Summary: The National Medical Products Administration (NMPA) issued an announcement on August 20, 2020, detailing findings from drug testing where 25 batches of drugs from 20 pharmaceutical companies were found to be non-compliant. Key manufacturers included Henan Furen Huaiqingtang Pharmaceutical Co., Ltd., Chengdu Tongde Pharmaceutical Co., Ltd., Shanxi Qianhui Pharmaceutical Co., Ltd., and Henan Tianzhi Pharmaceutical Co., Ltd., among others. Main violations encompassed critical quality issues such as solution clarity and color, presence of visible foreign matter, elevated microbial counts (total mold, yeast, and aerobic bacteria), incorrect appearance, deviations in acid-insoluble ash content, fill weight uniformity, moisture levels, identification, and content determination. These products failed to meet standards outlined in the Pharmacopoeia of the People's Republic of China and various National Drug Standards. In response, the NMPA mandated immediate risk control measures, including suspending sales, recalling affected drugs, and requiring companies to investigate root causes and implement effective rectification. Provincial drug regulatory authorities were further instructed to investigate these breaches in accordance with the "Drug Administration Law of the People's Republic of China" and publicly disclose their findings.

Company: https://www.globalkeysolutions.net/companies/guangxi-yulin-huaantang-traditional-chinese-medicine-pieces-co-ltd/12088ba5-957b-470a-bc17-ee79f5faed41/